Cargando…

Ramucirumab: A New Therapy for Advanced Gastric Cancer

Detalles Bibliográficos
Autores principales:	Oholendt, Andrea Landgraf, Zadlo, Jennifer L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577036/ https://www.ncbi.nlm.nih.gov/pubmed/26413377

Ejemplares similares

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer
por: Mehta, Rutika, et al.
Publicado: (2020)

Bronchobiliary fistula after ramucirumab treatment for advanced gastric cancer: A case report
por: Kim, Hong-Beum, et al.
Publicado: (2019)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
por: Kawai, Sadayuki, et al.
Publicado: (2020)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
por: Li, Sini, et al.
Publicado: (2020)

Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
por: Rezvani, Hamid, et al.
Publicado: (2022)

Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma
por: Nishioka, Naoya, et al.
Publicado: (2018)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan
por: Chen, Yucherng, et al.
Publicado: (2021)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
por: Cooper, Maryann R, et al.
Publicado: (2016)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel
por: Rakusic, Zoran, et al.
Publicado: (2020)

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer
por: Sorokin, Maxim, et al.
Publicado: (2020)

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
por: Yang, Hongqiong, et al.
Publicado: (2021)

Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study
por: D’Alessandro, Rosalba, et al.
Publicado: (2022)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety, Dipesh
Publicado: (2019)

Endoscopic Ultrasound-Guided Drainage of Intra-Abdominal Abscess after Gastric Perforation in a Patient Receiving Ramucirumab and Paclitaxel for Advanced Gastric Cancer
por: Mandai, Koichiro, et al.
Publicado: (2017)

A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
por: Urakawa, Shinya, et al.
Publicado: (2017)

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study
por: D’Alessandro, Rosalba, et al.
Publicado: (2023)

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial
por: Yamaguchi, Kensei, et al.
Publicado: (2020)

Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report
por: Yang, Min Joo, et al.
Publicado: (2021)

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
por: Chen, Ming-Huang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bk20ahmb2k9fssu9et2v7ik4eu